AOH1160

Cat. No.:	HY-120836
CAS No.:	2089314-57-6
Molecular Formula:	$C_{25}H_{20}N_2O_3$
Molecular Weight:	396.44
Target:	DNA/RNA Synthesis; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (252.24 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5224 mL	12.6122 mL	25.2245 mL
5 mM	0.5045 mL	2.5224 mL	5.0449 mL
10 mM	0.2522 mL	1.2612 mL	2.5224 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

AOH1160 is a potent oral small molecule proliferating cell nuclear antigen (PCNA) inhibitor that interferes with DNA replication, blocks homologous recombination-mediated DNA repair, leads to cell cycle arrest and induces apoptosis[1].

IC_{50} & Target

IC50: PCNA[1]

In Vitro

AOH1160 (500 nM, 48 h) can lead to tumor cell cycle arrest and induce tumor cell apoptosis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line:	SAEC, H524
Concentration:	500 nM
Incubation Time:	6, 24 h

	Result:	Caused cell cycle arrest. Increased in the sub-G1 population in neuroblastoma and small cell lung cancer cells.
	Western Blot Analysis[1]	
	Cell Line:	SAEC, H524
	Concentration:	500 nM
	Incubation Time:	6, 24, 48 h
	Result:	Increased γH2A.X levels and activated caspase-3 and caspase-9.
In Vivo	AOH1160 (40 mg/kg, gavage once a day) can inhibit the growth of breast cancer and small cell lung cancer in mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Gu L, et al. The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res. 2018 Dec 1;24(23):6053-6065.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA